A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
NCT03075826
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Myeloproliferative Neoplasms
Interventions
DRUG:
SGI-110
Sponsor
Weill Medical College of Cornell University
Collaborators
[object Object]